Natera partners with TransCode for cancer trial enrollment

Natera Inc. (NTRA) and TransCode Therapeutics Inc. (RNAZ) announced a collaboration to enroll patients in a colorectal cancer clinical trial using Natera's Signatera test to identify eligible patients. The trial targets patients at risk of recurrence but with no approved therapies. TransCode's TTX-MC138 aims to inhibit a biomarker linked to metastatic cancers. The trial is part of the PRE-I-SPY program and is registered at clinicaltrials.gov.

Original reporting
Published Oct 13, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NTRA
Bullish
high confidence
Mentioned
$NTRA · $RNAZ
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NTRABullishMed
01

Why it matters

The collaboration creates a pipeline for enrolling MRD‑positive colorectal cancer patients, potentially accelerating trial timelines and generating data that could support future regulatory filings.

02

Market read

Both companies stand to benefit from the partnership, with Natera gaining a new commercial application for its test and TransCode improving trial enrollment efficiency.

03

What to watch

The partnership does not guarantee commercial success; regulatory approval, trial outcomes, and reimbursement pathways remain uncertain.

Relevance 7/10Novelty 7/10Timing: today

Background

Natera's Signatera test detects molecular residual disease (MRD) in cancer patients, while TransCode's TTX‑MC138 is an RNA‑based therapeutic targeting microRNA‑10b.

Company-level read

Ticker impact

$NTRABullishHigh confidence
Context

Natera announced a collaboration with TransCode to use its Signatera test for enrolling patients in a colorectal cancer Phase 2a trial.

Expected impact

likely upward pressure as investors price in potential test volume growth

Evidence & confidence

First disclosure of a clinical‑trial enrollment partnership; biotech investors typically react positively to new commercial applications of a diagnostic platform.

$RNAZBullishMedium confidence
Context

TransCode Therapeutics disclosed the partnership with Natera to identify MRD‑positive patients for its TTX‑MC138 trial.

Expected impact

moderate upside as the trial may progress faster with identified patients

Evidence & confidence

First public announcement of a collaboration that could improve trial efficiency; impact depends on later trial results.

Market effects

Highlights growing integration of liquid biopsy diagnostics in oncology trial design, potentially benefiting the broader molecular diagnostics sector.

U.S. biotech investors may see increased interest in companies offering companion diagnostics for immuno‑oncology.

The collaboration underscores the importance of precision medicine globally, but immediate market impact is limited to the two U.S. listed firms.

Counterpoint

If the trial fails to enroll patients or does not show efficacy, the partnership could be viewed as a cost without benefit, pressuring both stocks.

Key entities

  • Natera Inc.

    Provider of the Signatera liquid biopsy test.

  • TransCode Therapeutics Inc.

    Developer of TTX‑MC138, an RNA‑based immuno‑oncology therapy.

Related articles

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

$NTRAMedAI 8/10

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.